143 related articles for article (PubMed ID: 9869594)
1. In vitro activities of six new fluoroquinolones against Brucella melitensis.
Trujillano-Martín I; García-Sánchez E; Martínez IM; Fresnadillo MJ; García-Sánchez JE; García-Rodríguez JA
Antimicrob Agents Chemother; 1999 Jan; 43(1):194-5. PubMed ID: 9869594
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey.
Kocagöz S; Akova M; Altun B; Gür D; Hasçelik G
Clin Microbiol Infect; 2002 Apr; 8(4):240-2. PubMed ID: 12047416
[TBL] [Abstract][Full Text] [Related]
3. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones.
García-Rodríguez JA; García Sánchez JE; Trujillano I; García Sánchez E; García García MI; Fresnadillo MJ
Antimicrob Agents Chemother; 1995 May; 39(5):1194-5. PubMed ID: 7625815
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of various antimicrobials against Brucella melitensis strains in the Aegean region in Turkey.
Yamazhan T; Aydemir S; Tünger A; Serter D; Gökengin D
Med Princ Pract; 2005; 14(6):413-6. PubMed ID: 16220015
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of tigecycline, tetracycline and fluoroquinolones against Brucella melitensis.
Kilic S; Dizbay M; Cabadak H
J Chemother; 2008 Feb; 20(1):33-7. PubMed ID: 18390405
[TBL] [Abstract][Full Text] [Related]
6. Activity of BAY y 3118, a novel 4-quinolone, against Brucella melitensis.
García-Rodríguez JA; García-Sánchez JE; Trujillano-Martín I; García-Sánchez E; García-García MI; Fresnadillo MJ
J Chemother; 1994 Apr; 6(2):102-6. PubMed ID: 8077983
[TBL] [Abstract][Full Text] [Related]
7. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
8. [Short communication: Investigation of in vitro antibiotic susceptibility of Brucella melitensis].
Alişkan H; Turunç T; Demiroğlu YZ; Colakoğlu S; Arslan H
Mikrobiyol Bul; 2008 Jan; 42(1):125-9. PubMed ID: 18444570
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
Saravolatz L; Manzor O; Check C; Pawlak J; Belian B
J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of azithromycin, trovafloxacin and grepafloxacin as prophylaxis against experimental murine Brucella melitensis infection.
Atkins HS; Spencer S; Brew SD; Jenner DC; Sefton AM; MacMillan AP; Brooks TJ; Simpson AJ
Int J Antimicrob Agents; 2010 Jul; 36(1):66-8. PubMed ID: 20022474
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi.
Kraiczy P; Weigand J; Wichelhaus TA; Heisig P; Backes H; Schäfer V; Acker G; Brade V; Hunfeld KP
Antimicrob Agents Chemother; 2001 Sep; 45(9):2486-94. PubMed ID: 11502519
[TBL] [Abstract][Full Text] [Related]
12. Anti-Brucella activity of Ro 23-9424, a dual-action antibacterial.
Qadri SM; Ueno Y; Ayub A
Chemotherapy; 1993; 39(6):386-9. PubMed ID: 8222864
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates.
Milatovic D; Schmitz FJ; Brisse S; Verhoef J; Fluit AC
Antimicrob Agents Chemother; 2000 Apr; 44(4):1102-7. PubMed ID: 10722524
[TBL] [Abstract][Full Text] [Related]
14. Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents.
Browne FA; Bozdogan B; Clark C; Kelly LM; Ednie L; Kosowska K; Dewasse B; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2003 Dec; 47(12):3815-24. PubMed ID: 14638489
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of Brucella melitensis isolates to various antimicrobials in Turkey.
Denk A; Demirdag K; Kalkan A; Ozden M; Cetinkaya B; Kilic SS
Infect Dis (Lond); 2015 Jun; 47(6):364-9. PubMed ID: 25712728
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Blondeau JM; Laskowski R; Bjarnason J; Stewart C
Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
[TBL] [Abstract][Full Text] [Related]
17. Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
Heinemann B; Wisplinghoff H; Edmond M; Seifert H
Antimicrob Agents Chemother; 2000 Aug; 44(8):2211-3. PubMed ID: 10898706
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of Salmonella typhi and Brucella melitensis to the new fluoroquinolone rufloxacin (MF 934).
Qadri SM; Ayub A; Ueno Y; Saldin H
Chemotherapy; 1993; 39(5):311-4. PubMed ID: 8396527
[TBL] [Abstract][Full Text] [Related]
19. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.
Brueggemann AB; Coffman SL; Rhomberg P; Huynh H; Almer L; Nilius A; Flamm R; Doern GV
Antimicrob Agents Chemother; 2002 Mar; 46(3):680-8. PubMed ID: 11850248
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs.
Ruiz-Serrano MJ; Alcalá L; Martínez L; Díaz M; Marín M; González-Abad MJ; Bouza E
Antimicrob Agents Chemother; 2000 Sep; 44(9):2567-8. PubMed ID: 10952620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
